Aurobindo Pharma Limited — Q2 FY25
Aurobindo Pharma delivered a steady Q2 FY25 with revenue of INR 7,796 crore (+8% YoY) and EBITDA margin of 20.1%, despite higher R&D costs and penicillin G ramp-up losses.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY25
FY25 EBITDA margin target of 21%-22%
Management reiterated the internal EBITDA margin target of 21%-22% for FY25, with potential revision in Q2 call.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY25
Pen-G plant ramp-up from October 2024
Pen-G plant expected to ramp up significantly from October 2024, with 80% capacity utilization targeted by Q3.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY25
China plant commercialization from Q3 FY25
China plant expected to start commercial production from Q3 FY25, with ramp-up from Q4 FY25.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1